Stopping GLP-1 drugs like Ozempic erodes heart health benefits quickly, new study finds

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by LSEG. Fox News senior medical analyst Dr. Marc Siegel discusses the benefits and risks of GLP-1 medications on 'Fox & Friends Weekend.' People who stop taking popular weight-loss and diabetes medications may lose out on any heart health benefits the medications provided. GLP-1 receptor agonists — such as semaglutide (Ozempic and Wegovy), and tirzepatide (Mounjaro and Zepbound) — have been shown to reduce the risk of heart attack and stroke. A new study from the Washington University School of Medicine in St. Louis explored the effects of quitting — particularly related to cardiovascular health. NEW OZEMPIC-ALTERNATIVE DIABETES PILL BURNS FAT WITHOUT MUSCLE LOSS, STUDY SUGGESTS "Many people are excited to start GLP-1s, but many stop within a few months," Ziad Al-Aly, senior clinical epidemiologist at WashU Medicine, told Fox News Digital. "Some research loo